Principal Investigator
Michele Stanchina
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20250293
Clinical Trial Summary
A Phase 2 Trial of Abbreviated Brentuximab Vedotin, Etoposide, Cyclophosphamide, Adriamycin, Dacarbazine, and Dexamethasone (BrECADD) Therapy in Stage IIB-IV Hodgkin Lymphoma
Phase
Phase II
Funding Agency/Sponsor
Institutional
Disease
Lymphoma
Contact Information
Phone Number
+1 (305) 2434624